Transgene SA

Transgene SA est membre de Lyonbiopôle

General information

400 Boulevard Gonthier d'Andernach Parc d'Innovation

67405 Illkirch-Graffenstaden

Incorporated in: 1979/12/30

Number of employees: 281

Turnover: €2 (in 2013)


More information

 

Main activity

Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S.


Funding

Looking for funding: Yes

Nature of funding searches: Transgene may seek to partner its programs in oncology and ID with pharmaceutical partners as they reach key pre-clinical or clinical development milestones. The Company is also leveraging its R&D capabilities through grant-supported collaborative programs with external organizations.

Public funding obtained: Transgene has a strong track record of fruitful collaboration with external partners and has been involved in more than 15 grant-supported collaborative programs

Stock exchange listing: NYSE Euronext Paris- Eurolist (compartment B)
Listed 26 March 1998 Nouveau Marché and Nasdaq (de-listed Nasdaq 2005)

Segmentation
Activities
Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine


Application market
Infectiology - Parasitology - Oncology


Activities
Therapeutics, Pharma or Biotech


Technologies
Cell Therapy - cell biology - Biobanking - Vaccine - Molecular Biology and Nucleic acid